Catégorie : Cannabis et Réduction des Risques

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists, Gniewko Wieckiewicz et al., 2022,

Cannabidiol (CBD) in the Self-Treatment of Depression-Exploratory Study and a New Phenomenon of Concern for Psychiatrists Gniewko Wieckiewicz, Iga Stokłosa, Maciej Stokłosa, Piotr Gorczyca and Robert Pudlo Frontiers in Psychiatry, March 2022 | Volume 13 | Article 837946 doi : 10.3389/fpsyt.2022.837946   Cannabis sativa, whose flowers are also known as marijuana or marihuana, is a recreational plant that contains many chemicals that are constantly being studied by scientists around the world. One of these substances is cannabidiol (CBD), which has gained widespread popularity on the internet as a cure for mental health problems, leading many people to use CBD to self-treat depression and anxiety. This [...]

Lire la suite

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety, Liz Scherer, Medscape.com, 2022

OTC Cannabidiol Products Tied to Improved Pain, Sleep, Anxiety Liz Scherer https://www.medscape.com/viewarticle/967088?uac=292598PZ&faf=1&sso=true&impID=4065214&src=mkm_ret_220305_mscpmrk_neuro_pain Medscape Medical News © January 24, 2022   Over-the-counter cannabidiol (CBD) products appear to improve pain, sleep, and anxiety disorders, preliminary research suggests. Interim findings from the Advancing CBD Education and Science (ACES), a 100% virtual, open label, randomized controlled trial, show study participants experienced various degrees of "clinically meaningful" improvements in sleep quality, anxiety, and pain. “ACES is the largest clinical trial ever conducted on commercially available CBD products and provides first-of-its-kind real world evidence into what conditions users may experience benefit from CBD usage, whether these benefits are clinically meaningful, what attributes of CBD [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, GRECC, version 3-5, mars 2022

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages       Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1]   En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]

Lire la suite

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins, Samuel D. Banister and Mark Connor, 2018

The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances : Origins Samuel D. Banister and Mark Connor Handbook of Experimental Pharmacology, # Springer International Publishing AG, part of Springer Nature 2018 doi : 10.1007/164_2018_143   Contents 1 Introduction 2 Chemical Classification of Synthetic Cannabinoid Receptor Agonists 3 Cannabinoid Type 1 Receptor (CB1) Structure and Function 4 Historical Synthetic Cannabinoid Receptor Agonists 4.1 Classical Cannabinoids and Phytocannabinoid Analogs 4.2 Nonclassical Cannabinoids 4.3 Aminoalkylindoles (AAIs) 5 Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances 5.1 Molecular Hybridization 5.2 Bioisosteric Fluorination 6 Conclusions References Abstract Synthetic cannabinoid receptor agonists (SCRAs) have proliferated as new psychoactive substances (NPS) over the past decade. Relative to other classes of NPS, SCRAs [...]

Lire la suite

Birth Outcomes of Neonates Exposed to Marijuana in Utero. A Systematic Review and Meta-analysis, Greg Marchand et al., 2022

Birth Outcomes of Neonates Exposed to Marijuana in Utero. A Systematic Review and Meta-analysis Greg Marchand, MD; Ahmed Taher Masoud, MD; Malini Govindan, MD; KellyWare, MS; Alexa King, BS; Stacy Ruther, BS; Giovanna Brazil, BS; Hollie Ulibarri, BS; Julia Parise, BS; Amanda Arroyo, BS; Catherine Coriell, BS; Sydnee Goetz, BS; Amitis Karrys, BS; Katelyn Sainz, MD JAMA Network Open, 2022, 5, (1), e2145653, 1-13. doi : 10.1001/jamanetworkopen.2021.45653   Abstract IMPORTANCE While some studies have found an association between marijuana use and adverse neonatal outcomes, results have not been consistent across all trials. OBJECTIVE To assess available data on neonatal outcomes in marijuana-exposed pregnancies. DATA SOURCES PubMed, Medline, ClinicalTrials.gov, [...]

Lire la suite

EDITORIAL : Cannabinoids in psychiatry : they are here to stay, Julia Jiyeon Woo et al., 2022

EDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216   Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training.   Vignette A young man sits in his psychiatrist’s office. After [...]

Lire la suite

Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants, Richard B. van Breemen et al., 2022

Cannabinoids Block Cellular Entry of SARS-CoV‑2 and the Emerging Variants Richard B. van Breemen, Ruth N. Muchiri, Timothy A. Bates, Jules B. Weinstein, Hans C. Leier, Scotland Farley, and Fikadu G. Tafesse Journal of Natural Products, 2022, 85, 176−184. Doi : 10.1021/acs.jnatprod.1c00946 ABSTRACT : As a complement to vaccines, small-molecule therapeutic agents are needed to treat or prevent infections by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its variants, which cause COVID-19. Affinity selection−mass spectrometry was used for the discovery of botanical ligands to the SARS-CoV-2 spike protein. Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, janvier 2022

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, janvier 2022. (5e version, janvier 2022....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 28 7 - Cannabinoïdes et Sommeil : 29 - 30 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57 11 - Cannabinoides et syndrome de Gilles [...]

Lire la suite

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior, Citlalli Netzahualcoyotzi et al., 2021

Early Consumption of Cannabinoids : From Adult Neurogenesis to Behavior Citlalli Netzahualcoyotzi, Luis Miguel Rodríguez-Serrano, María Elena Chávez-Hernández and Mario Humberto Buenrostro-Jáuregui International Journal of Molecular Sciences, 2021, 22, 7450. doi : 10.3390/ijms22147450   Abstract The endocannabinoid system (ECS) is a crucial modulatory system in which interest has been increasing, particularly regarding the regulation of behavior and neuroplasticity. The adolescent–young adulthood phase of development comprises a critical period in the maturation of the nervous system and the ECS. Neurogenesis occurs in discrete regions of the adult brain, and this process is linked to the modulation of some behaviors. Since marijuana (cannabis) is the most consumed illegal [...]

Lire la suite

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomizedplacebo-controlled trial, Violaine Mongeau-Pérusse, et al., 2021

Cannabidiol as a treatment for craving and relapse inindividuals with cocaine use disorder: a randomized placebo-controlled trial Violaine Mongeau-Pérusse, Suzanne Brissette, Julie Bruneau, Patricia Conrod, Simon Dubreucq, Guillaume Gazil, EmmanuelStip & DidierJutras-Aswad Addiction, 2021, 116, (9), 1-12. Doi : 10.1111/add.15417   ABSTRACT Background and Aims : Cocaine use disorder (CUD) is a significant public health concern for which no efficacious phar-macologicalinterventionsare available. Cannabidiol (CBD) has attracted considerable interest as a promisingtreatmentforaddiction. This study tested CBD efficacy for reducing craving and preventing relapse in people with CUD.DesignSingle-site double-blind randomized controlled superiority trial comparing CBD with placebo. Setting and Participants : Centre Hospitalier de l’Université de Montréal, Canada. Seventy-eight [...]

Lire la suite